Company Information
Company Profile
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.
LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.
Latest Presentations
Oppenheimer's 33rd Annual Healthcare Conference Presentation
View This Presentation
Cerecor | AEVI Merger Details
Please see the attached to documents for detailed information regarding the Aevi acquisition / merger and or a simple question and answer document
Name | View Document |
---|---|
CERECOR SEC S4 Aevi Acquisition | Download |
CERECOR Q&A Document | Download |
Contact Information
Investor Relations
Avalo Therapeutics
ir@avalotx.com
ICR Westwicke
Chris Brinzey
Managing Director
T: 339-970-2843
chris.brinzey@westwicke.com
Company Contact
Avalo Therapeutics, Inc.
1500 Liberty Ridge Drive
Wayne, PA 19087